In terms of targeted therapy, new ADCs such as T‐DXd not only combine the selectivity of targeted therapy and the cytotoxicity of chemotherapy, but also have a “bystander killing effect,” and have achieved remarkable results in the treatment of HER2‐positive and HER2‐low breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.